Nexstim Oyj: Nexstim Receives an NBT System Order from a New Therapy Customer in Finland
Therapy Customer in Finland
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that it has received a new NBT System order from a therapy customer in Finland.
This is a new customer for Nexstim and the system will be used to treat Major Depressive Disorder (MDD).
Nexstim s NBT System with SmartFocus nTMS is highly differentiated from other currently available TMS products due to its unique and highly sophisticated 3D navigation that uses its proprietary E-field algorithm to visualize the exact location, orientation, and magnitude of the stimulation.
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim Oyj: Nexstim Plc Business and Clinical Update Q1 2021 Q1 2021
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces the key highlights of the Company s business and clinical progress during Q1 2021.
CEO Mikko Karvinen s
pdate
Glad to inform that our operational business has had the best start of the year ever while beginning our first full year of executing our renewed strategy. During the first months of 2021, we have continued to invest in the growth of our diagnostic and therapeutic business with the recruitment of two new sales team members to our US organization. At the same time, we are extremely pleased to see that our existing NBS and NBT System customer base has increased the utilisation rate of our installed base to a record level. High utilization of the systems leads into growing levels of high margin recurring revenue, an important element in our profitable growth strategy.
Nexstim Oyj
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST)
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT® Systems to Treat MDD
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that the company’s SmartFocus® nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression.
(0)
Press release, Helsinki, 16.04.2021, 12.00 pm (EEST)
Nexstim Receives Positive Feedback from Mind Matters Psychiatry MD on Use of Their Two NBT Systems to Treat MDD
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ( Nexstim or Company ) announces that the company s SmartFocus nTMS technology used at Mind Matters Psychiatry MD, US has generated positive feedback from its use in treating patients with depression.
Oladele Adebogun M.D. said, I was initially introduced to Nexstim by the early outcomes of their registry which showed 50% remission rates in a small number of patients suffering from major depressive disorder. I purchased my first system and have been so impressed with my own patient outcomes that I have added this second system for my patients located in Flower Mound, Texas. I have even been able to successfully treat those patients who failed to respond to TMS on our prior non-Nexstim system. I am proud to contribute to the latest Nexstim treatment outcomes of triple the num